血清5-羟色胺、CX3C趋化因子配体1对急性脑梗死后睡眠障碍的预测价值OA

Objective To explore the predictive value of serum 5-hydroxytryptamine(5-HT)and chemokine C-X3-C ligand 1(CX3CL1)on sleep disorders after acute cerebral infarction(ACI).Methods The Pittsburgh sleep quality index(PSQI)was used to evaluate the sleep status of 93 patients with ACI,and they were divided into sleep disorder group and control group.The levels of serum 5-HT and CX3CL1 were determined by ELISA.Spearman rank correlation analysis was used to analyze the correlation between serum 5-HT,CX3CL1 levels and PSQI total score.Logistic analysis was used to analyze the factors affecting sleep disorders in ACI patients.The ROC curve was used to analyze the predictive value of serum 5-HT and CX3CL1 for sleep disorders in ACI patients.Results At 6 months of follow-up,34 cases(36.56%)of 93 ACI patients had sleep disorders.Compared with those in the control group,the serum 5-HT level was significantly decreased,and the CX3CL1 level was significantly increased in the sleep disorder group(all P<0.001).The total score of PSQI in ACI patients was negatively correlated with the level of 5-HT(rs=-0.526,P<0.05),and positively correlated with the level of CX3CL1(rs=0.553,P<0.05).Logistic regression analysis showed that serum 5-HT was a protective factor for ACI sleep disorder(P<0.05),and serum CX3CL1 was an independent risk factor for ACI sleep disorder(P<0.05).The ROC curve showed that the combined prediction of 5-HT and CX3CL1 was better than that of serum 5-HT and CX3CL1 alone in predicting ACI sleep disorder(Z=2.563,P=0.010;Z=2.808,P=0.005).Conclusion Serum 5-HT and CX3CL1 are closely related to sleep disorders in ACI,and have certain predictive value for sleep disorders in ACI.